Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of the combination of capecitabine and oxaliplatin in the
1st, 2nd or subsequent line treatment of metastatic colorectal cancer, and also in the
neo-adjuvant and adjuvant setting of resectable metastases.
Primary Endpoint: Objective response rates
Secondary Endpoints: Treatment related toxicity Progression free survival (If not resected)
Disease free Survival (From metastastectomy, if resected) Overall Survival 60 Day all cause
mortality Number undergoing liver resections/curative resection (Ro) rate